

Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19

Anna H.E. Roukens¹, Marion König², Tim Dalebout³, Tamar Tak², Shohreh Azimi², Yvonne Kruize², Cilia R. Pothast⁴, Renate S. Hagedoorn⁴, Sesmu M. Arbous⁵, Jaimie L. H. Zhang¹, Maaike Verheij¹, Corine Prins¹, Anne M. van der Does⁶, Pieter S. Hiemstra⁶, Jutte J.C. de Vries³, Jacqueline J. Janse², Meta Roestenberg^{1,2}, Sebenzile K. Myeni³, Marjolein Kikkert³, Mirjam H.M. Heemskerk⁴, Maria Yazdanbakhsh², Hermelijn H. Smits^{2,#}, Simon P. Jochems^{2,#}, in collaboration with BEAT-COVID group*, also in collaboration with COVID-19 LUMC group[&].

1. Dept. of Infectious Diseases, LUMC.
2. Dept. of Parasitology, LUMC
3. Dept. of Medical Microbiology, LUMC
4. Dept. of Hematology, LUMC
5. Dept. of Intensive Care, LUMC
6. Dept. of Pulmonology, LUMC

#Joint senior authors

correspondence to be addressed to: s.p.jochems@lumc.nl

*BEAT-COVID study group (in alphabetical order, IR): M.S. Arbous¹, B.M. van den Berg², S. Cannegieter³, C.M. Cobbaert⁴, A. M. van der Does⁵, J.J.M. van Dongen⁶, J. Eikenboom⁷, M.C.W. Feltkamp⁸, A. Geluk⁹, J.J. Goeman¹⁰, M. Giera¹¹, T. Hankemeier¹², M.H.M. Heemskerk¹³, P.S. Hiemstra⁵, C.H. Hokke¹⁴, J.J. Janse¹⁴, S.P. Jochems¹⁴, S.A. Joosten⁹, M. Kikkert⁸, L. Lamont¹², J. Manniën¹⁰, T.H.M. Ottenhoff⁹, T. Pongracz¹¹, M.R. del Prado¹, N. Queralt Rosinach¹⁵, M. Roestenberg^{9,14}, M. Roos¹⁵, A.H.E. Roukens⁹, H.H. Smits¹⁴, E.J. Snijder⁸, F.J.T. Staal⁶, L.A. Trouw⁶, R. Tsonaka¹⁰, A. Verhoeven¹¹, L.G. Visser⁹, J.J.C. de Vries⁸, D.J. van Westerloo¹, J. Wigbers¹, H.J. van der Wijk¹⁰, R.C. van Wissen⁴, M. Wuhrer¹¹, M. Yazdanbakhsh¹⁴, M. Zlei⁶

1. Dept. of Intensive Care, LUMC
2. Dept. of Internal Medicine, Nephrology, LUMC
3. Dept. of Clinical Epidemiology, LUMC
4. Dept. of Clinical Chemistry, LUMC
5. Dept. of Pulmonology, LUMC
6. Dept. of Immunology, LUMC
7. Dept. of Internal Medicine, Thrombosis and Hemostasis, LUMC
8. Dept. of Medical Microbiology, LUMC
9. Dept. of Infectious Diseases, LUMC
10. Dept. of Biomedical Data Sciences, LUMC
11. Center for Proteomics and Metabolomics, LUMC
12. Division of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, the Netherlands
13. Dept. of Hematology, LUMC
14. Dept. of Parasitology, LUMC
15. Dept. of Human Genetics, LUMC

&COVID-19 LUMC group (IR): Josine A. Oud, MSc¹; Meryem Baysan, MSc^{2,3}; Jeanette Wigbers²; Lieke J. van Heurn, BSc³; Susan B. ter Haar, BSc³; Alexandra G.L. Toppenberg, BSc³; Laura Heerdink³, BSc; Anneke A. van IJzinga Veenstra, BSc³; Anna M. Eikenboom, BSc³; Julia M. Wubbolts, MSc⁴; Jonathan Uzorka MD⁴, Willem Lijfering MD PhD³; Romy Meier¹; Ingeborg de Jonge³; Sesmu M. Arbous MD PhD²; Mark G.J. de Boer MD PhD⁴; Anske G. van der Bom, MD PhD³; Olaf M. Dekkers, MD PhD³; Frits Rosendaal, MD PhD³

1. Dept. of Hematology
2. Dept. of Intensive Care, LUMC
3. Dept. of Clinical Epidemiology, LUMC
4. Dept. of Infectious Diseases, LUMC

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 The immune system plays a major role in Coronavirus Disease 2019 (COVID-19)
3 pathogenesis, viral clearance and protection against re-infection. Immune cell dynamics
4 during COVID-19 have been extensively documented in peripheral blood, but remain elusive
5 in the respiratory tract. We performed minimally-invasive nasal curettage and mass cytometry
6 to characterize nasal immune cells of COVID-19 patients during and 5-6 weeks after
7 hospitalization. Contrary to observations in blood, no general T cell depletion at the nasal
8 mucosa could be detected. Instead, we observed increased numbers of nasal granulocytes,
9 monocytes, CD11c⁺ NK cells and exhausted CD4⁺ T effector memory cells during acute
10 COVID-19 compared to age-matched healthy controls. These pro-inflammatory responses
11 were found associated with viral load, while neutrophils also negatively correlated with oxygen
12 saturation levels. Cell numbers mostly normalized following convalescence, except for
13 persisting CD127⁺ granulocytes and activated T cells, including CD38⁺ CD8⁺ tissue-resident
14 memory T cells. Moreover, we identified SARS-CoV-2 specific CD8⁺ T cells in the nasal
15 mucosa in convalescent patients. Thus, COVID-19 has both transient and long-term effects
16 on the immune system in the upper airway.

17

18 Main

19 Individuals infected with SARS-CoV-2 suffer from a wide range of symptoms, ranging from
20 none to fever, cough and dyspnea and severe acute respiratory distress syndrome, which can
21 culminate in death¹. The immune cell perturbations during COVID-19 have been described
22 extensively in blood, with changes observed in almost all immune cell populations that often
23 could be linked to disease severity. A global depletion of peripheral blood T cells has been
24 proposed to be a hallmark of COVID-19^{2,3}. At the same time, neutrophil numbers are strongly
25 increased and an increased neutrophil to lymphocyte ratio is associated with poor prognosis
26⁴. Natural killer (NK) cells show an activated profile, associating with disease severity⁵.
27 Myeloid cells show an aberrant profile with increased proliferation and altered functionality^{6,7}.
28 The B cell compartment is characterized by oligoclonal expansion of plasmablasts and
29 extrafollicular B cells^{8,9}. Eosinophils were found to be decreased in blood in most patients at
30 time of hospital admission¹⁰. However, eosinophils might expand during hospitalization and
31 show upregulated levels of the homing marker CD62L and activation profiles, which was found
32 to precede lung hyperinflammation¹¹.

33 Although SARS-CoV-2 mainly replicates in the respiratory tract, and lower respiratory tract
34 complications are major drivers of morbidity and mortality, it is unclear to what extent
35 immunological dynamics observed in blood can be translated to the respiratory tract. Indeed,
36 cytokines and antibodies do not seem to correlate between the nasopharynx and peripheral
37 blood during COVID-19¹². Several studies already investigated mucosal immune responses
38 using either bronchoalveolar lavage (BAL)¹³ or nasopharyngeal and oropharyngeal swabs¹⁴
39 from hospitalized patients, demonstrating increased neutrophil levels and activated alveolar
40 macrophages/monocytes during COVID-19. T cell recruitment to the respiratory tract might be
41 beneficial, as an expansion of CD8⁺ T cell receptor (TCR) clones in BAL has been reported in
42 moderate compared to critical cases¹³. Another study with severe COVID-19 patients found
43 that increased CD4⁺ T cells in tracheal aspirates associated with survival¹⁵. In addition to
44 these findings, several other studies have used nasopharyngeal swabs (NPS) to analyse local
45 responses^{16,17}. However, NPS collect cells only very superficially and mainly provide epithelial
46 and luminal infiltrating cells such as neutrophils and monocytes, while other immune cells,
47 such as T cells are incompletely captured. In contrast, BAL samples and tracheal aspirates
48 provide a clear picture of the lower airways¹⁸⁻²¹, but are difficult to collect longitudinally, after
49 recovery, or from healthy controls and patients that do not require intubation. Moreover,
50 studies performed on tissue are usually done in severe patients that died from the infection,
51 which creates a bias in the outcomes. As a result, we still have limited understanding of how
52 COVID-19 affects mucosal immunity²². In the current study, we aimed to characterize immune
53 cell dynamics in the upper respiratory tract mucosa during the acute phase and early and later
54 recovery of COVID-19 disease and assess whether alterations persist during convalescence.

55 To this end, we performed a prospective observational cohort study, for which we recruited
56 patients with PCR-confirmed SARS-CoV-2 infection after hospital admission (Figure 1a).
57 Nasal curettage samples from 20 patients during hospitalization with up to 4 samples per
58 patient were collected and analysed in-depth using mass cytometry. The earliest samples were
59 collected 11 days after symptom onset, which corresponded to 2 days after admission, while
60 the latest sample was collected 82 days after onset (61 days after admission). To address this
61 large temporal range, we stratified hospitalized patients further into those with acute infection
62 (n=9, 2-11 days since admission) or those in early recovery stage (ERS) as defined by having
63 moved from the intensive care unit (ICU) to ward (n=11, 15-61 days since admission, with an
64 ICU stay for a period of 4-55 days). Patient characteristics, co-morbidities, outcome and
65 treatment are shown in Supplementary table 1. Sixteen patients were also sampled 5-6 weeks
66 after hospital discharge (convalescent patients, 42-119 days post symptom onset, with a

67 median of 77 days post onset). In addition, 12 sex and age-matched healthy controls with
68 negative SARS-CoV-2 IgG and no history of symptoms of airway infection were included. In
69 total, 875,564 nasal CD45⁺ immune cells were analysed from a total of 56 samples, comprising
70 of 44 samples collected from 29 COVID-19 patients and 12 samples from healthy donors.

71 Immune populations were analysed using a 39-marker mass cytometry panel (Supplementary
72 table 2). Nasal CD45⁺ immune cells were divided into 8 main lineages, which were further sub-
73 clustered into 28 populations (Figure 1b, c). At a lineage level, the nasal immune profile of
74 acute COVID-19 patients was dominated by granulocytes (median 97.2% of all immune cells,
75 IQR: 95.2-97.4%) (Figure 2a). This progressively decreased as granulocyte frequencies were
76 slightly lower in ERS (median 94.8%, IQR: 88.2-97.5%) and even further reduced in
77 convalescent patients (median 78.5%, IQR: 58.8-87.4%), more similar to healthy age-matched
78 donors (median 64%, IQR: 47.3-79.4%). All other lineages, with the exception of monocytes,
79 were decreased during acute infection compared to healthy donors. To understand whether
80 this apparent depletion was related to the increased numbers of granulocytes and monocytes
81 or a true lymphopenia, we performed a normalization step to epithelial cells for each sample.
82 This approach permits an independent assessment of different immune cell populations, while
83 allowing correction for variable sample yield. In healthy donors and recovered patients there
84 was a strong correlation between epithelial and immune cell yields, as expected, while this
85 association was absent in hospitalized patients (Figure 2b). This then suggests that the vastly
86 increased granulocyte numbers within the immune cell analysis are caused by a strong influx
87 of granulocytes into the nasal mucosa of patients. Indeed, when normalizing to epithelial cells,
88 granulocytes and monocytes were highly increased during acute infection and ERS compared
89 to healthy donors (Figure 2c). There was a trend for granulocytes to remain elevated during
90 convalescence compared to the healthy donors (median 0.26 granulocytes per epithelial cell,
91 IQR: 0.09-0.56 in convalescence, versus a median of 0.12, IQR: 0.07-0.20 in healthy donors),
92 although this was not statistically significant (Figure 2c and Supplementary table 3). None of
93 the other main cell lineages: B cells, NK cells, monocytes, pDC, mDC, CD4⁺ T cells and CD8⁺
94 T cells were statistically different between acute infection and controls. The observation that
95 there is no increase or decrease of total T cell numbers in the nasal mucosa is in contrast with
96 the general T cell depletion that has been observed in peripheral blood ^{2,3,6,7,23}.

97 On the sub-clustering level (Figure 1b, c), 8 of the 28 defined cell clusters were significantly
98 elevated during various stages of COVID-19, with a clear association with time from hospital
99 admission (Figure 3a,b and Supplementary tables 3 and 4). Three monocyte/macrophage
100 populations were defined, based on expression of CD163 and CD206, and all three were
101 increased during acute infection and ERS compared to convalescent patients and to healthy
102 donors. As expected, subsets of granulocytes were also increased, although with slightly
103 different dynamics during acute infection: CD16^{hi} neutrophils were elevated during acute stage
104 and to a lesser degree in ERS (median of 121.7x and 12.8x increased compared to healthy
105 donors, respectively). CD16^{dim} neutrophils were even more strongly increased during acute
106 infection (median 256.8x) and ERS (median 11.9x). Such CD16^{dim} neutrophils might
107 correspond to activated neutrophils as previously they have been shown to correlate with
108 nasal myeloperoxidase levels and/or they might be related to immature banded neutrophils,
109 recently released from the bone marrow ^{24,25}. Furthermore, CD16^{neg} granulocytes, which may
110 in part consist of eosinophils, were increased compared to controls 254.1x and 24.3x during
111 acute stage and ERS, respectively. Although there was no overall change in CD4⁺ T cell
112 numbers, there was a significant increase (median 18.0x) in effector memory (EM, CCR7⁻
113 CD45RO⁺) CD4⁺ T cells during the acute phase. And although not statistically significant, CD8⁺
114 T effector memory cells re-expressing CD45RA (EMRA: CCR7⁻ CD45RA⁺) also showed a
115 trend towards increased levels during acute infection compared to healthy donors (median
116 10.4x increased during acute infection). These findings agree with reports from peripheral

117 blood T cell responses during SARS-CoV-2 infection describing that more specific CD4⁺ T
118 cells are being induced than CD8⁺ T cells, and that the majority of specific CD8⁺ T cells are of
119 a T EMRA phenotype^{26,27}. Levels of these short-lived effector cells returned more or less to
120 numbers observed in healthy donors during ERS and convalescence. Finally, an additional
121 population that was increased in hospitalized patients (both acute and ERS), compared to
122 convalescent stage and healthy donors, were the CD11c⁺ NK cells, which might indicate a NK
123 cell population with increased interferon-producing capacity and effector function²⁸. Thus,
124 dynamic recruitment of various adaptive and innate populations mediating inflammation and
125 antiviral function to the upper respiratory tract was observed during hospitalization with cell
126 type numbers in convalescence that closely resembled levels measured in healthy donors. Of
127 note, we did not observe an increase in nasal B cells in hospitalized patients, which
128 corroborates observations that mucosal antibody levels seem reduced compared to systemic
129 titres in hospitalized patients^{12,29}.

130 Next, we analysed whether immune cell types correlated with each other as well as with
131 clinical characteristics during COVID-19 (Figure 3c). Focusing on samples from hospitalized
132 patient, a clear cluster of subsets with positively correlated frequencies was observed, which
133 included monocyte subsets, granulocyte subsets and CD4⁺ T EM and CD8⁺ T EMRA cells.
134 Most of these subsets negatively correlated with days since symptom onset and hospital
135 admission (see also the time-based plots in Supplementary figure 1), indicating that during
136 longer hospitalization the numbers of these cells gradually return to normal levels. Among all
137 cell types, the monocyte subsets, CD16^{neg} granulocytes and CD16^{dim} neutrophils correlated
138 positively with viral load (Figure 3c), suggesting that SARS-CoV-2 virus infection dose-
139 dependently induced nasal recruitment of various immune subsets. We also correlated cell
140 numbers with measurements of disease severity obtained at the same day as nasal sampling,
141 including breathing rate, oxygen saturation and serum CRP concentrations. This revealed that
142 CD16^{hi} neutrophils numbers, as well as total numbers of granulocytes, in nasal mucosa
143 negatively correlated with oxygen saturation levels. As expected, oxygen saturation also
144 negatively associated with applied oxygen flow, but not with viral load. This suggests that
145 fluctuations in viral titers are not related to disease worsening, while the enhanced presence
146 of nasal granulocyte populations is, similar to what has been described for granulocyte
147 numbers in peripheral blood. To understand whether factors like sex, co-morbidities and
148 medication were drivers of nasal immune profiles, we performed multi-dimensional scaling
149 using all cell subsets (Supplementary figure 2). Acute patients clearly clustered separately
150 from healthy donors and convalescent patients, with ERS patients intermediate. Therefore,
151 we visualized covariates separately per group (acute, ERS, convalescent, healthy), showing
152 there was no clear clustering based on any of these covariates, although larger sample sizes
153 might be needed to conclusively exclude any such effects.

154 Subsequently, we looked more closely at phenotypic expression profiles on the differentially
155 abundant cell clusters and to what extent these profiles normalized after hospital discharge.
156 Although all monocyte subsets significantly increased during acute infection, patients had
157 relatively more CD163⁺ and fewer CD163⁺ CD206⁺ monocytes/macrophages compared to
158 healthy donors, which normalized during recovery (Figure 4a). These CD206⁺ cells are likely
159 fully differentiated tissue-resident macrophages³⁰. CD163⁺ monocytes were also found
160 abundantly in peripheral blood of COVID-19 patients as well as in autopsy lungs and likely
161 represent a recently recruited monocyte population, a hypothesis that was supported by
162 trajectory analysis (Figure 4b)¹⁵. Of note, we did not observe non-classical or transitional
163 (CD16⁺) monocytes in the nasal mucosa (Figure 1c). Among all monocyte/macrophage
164 populations, HLA-DR expression was reduced during acute infection and ERS, which
165 normalized in convalescent patients (Figure 4c and Supplementary figure 3). Reduced HLA-
166 DR expression is a characteristic of myeloid-derived suppressor cells, and the expansion of

167 cells in peripheral blood resembling monocyte-derived suppressor cells has been previously
168 reported during severe COVID-19^{31,32}. Our results suggest that these cells may rapidly seed
169 the upper airway mucosa where they might further differentiate and acquire a macrophage
170 phenotype. CD163⁺ CD206⁺ monocytes/macrophages also expressed elevated levels of the
171 IL-3 receptor CD123 during both acute phase and ERS, while CD163⁺ and CD163⁻ monocyte
172 subsets generally lacked CD123. The expression of CD123 on tissue macrophages has been
173 previously described in patients with histiocytic necrotizing lymphadenitis³³. The functional
174 consequences of this upregulation of the IL3R on nasal macrophages during COVID-19
175 remain to be elucidated, but this finding further supports the importance of the IL-3/IL3-R axis
176 in COVID-19³⁴.

177 We then investigated more closely CD16⁻ granulocytes, by further grouping them into 7 sub-
178 clusters (Figure 4d). Sub-cluster 1, characterized by increased CD127 expression, was
179 significantly increased in patients during hospitalization (median 28.3%) but also during
180 convalescence (median 22.2%) compared to healthy donors (median 5.8%, Figure 4e,f). It
181 has been shown that engagement of IL-7 with its receptor CD127 on eosinophils leads to
182 increased survival and activation of eosinophils; and in airway allergen challenge in allergic
183 asthmatics, IL-7 levels in BAL strongly correlated with eosinophils³⁵. Thus while total numbers
184 of granulocytes returned to similar levels as observed in healthy donors, alterations in their
185 phenotype, and possibly their functionality, remained visible during convalescence. The half-
186 life of granulocytes is in the region of hours to days, suggesting either an ongoing recruitment
187 of altered cells or the continued local perturbation after or during entering the respiratory
188 mucosa³⁵.

189 The subset of CD4⁺ EM T cells was also increased during acute infection. To investigate their
190 phenotype more closely, we analysed the expression of markers of activation (CD38, HLA-
191 DR), exhaustion (PD1) or inhibition (CTLA-4) on these cells (Figure 5a). CD38 and CTLA4
192 were increased during the acute phase, but normalized at later timepoints, while HLA-DR and
193 PD1 remained expressed at a higher level even during convalescence as compared to healthy
194 donors. This induction of regulatory and inhibitory markers mirrors what has been described
195 in blood and likely reflects attempts of the immune system to restrain excessive activation.
196 Finally, we aimed to assess whether long-term protective CD8⁺ T cell immunity develops in
197 nasal mucosa to serve as gatekeepers against re-infections. Mouse models have shown that
198 nasal CD8⁺ tissue-resident memory (TRM) T cells specific for influenza persisted in nasal
199 mucosa following infection and efficiently controlled secondary infections³⁶. The majority of
200 nasal CD8⁺ T cells in our samples highly expressed CD69, which is used to define resident-
201 memory T cells³⁷, while very few naïve CD8⁺ T cells were present. Although it is possible that
202 some activated CD8⁺ T cells upregulate CD69 without being true TRM, the cluster of CD8⁺
203 TRM expressed very little KLRG1, which is congruent with a TRM phenotype (Figure 1c)³⁸.
204 Sub-clustering of CD8⁺ TRM showed variable expression of activation markers CD38, HLA-
205 DR and Tbet (Figure 5b). Within this embedding, CD8⁺ TRM from acute phase, ERS,
206 convalescent patients and controls clustered differentially, indicative of altered phenotypes
207 during and following COVID-19 (Figure 5c). Indeed, sub-cluster frequencies significantly
208 differed between the groups (Figure 5d, e). Sub-cluster 5, marked by expression of HLA-DR,
209 Tbet and CD38, was increased in hospitalized patients, while sub-cluster 3, expressing only
210 HLA-DR and CD38, was higher in convalescent patients compared to healthy donors, as were
211 all CD38⁺ TRMs. Thus CD8⁺ TRM had an increased activation profile, which persisted at least
212 5-6 weeks after hospital discharge. To demonstrate antigen specificity, we then attempted to
213 compare the T cell receptor (TCR) repertoire in nasal samples from convalescent patients with
214 SARS-CoV-2 reactive CD8⁺ and CD4⁺ T cells isolated from paired peripheral blood
215 (Supplementary figure 4). For one severe, convalescent patient we obtained >10 unique TCRs
216 from both nasal cells and sorted SARS-CoV-2 specific peripheral blood cells (Supplementary

217 figure 5). The TCR repertoire in the nasal mucosa of this patient was broad (218 unique TCRs),
218 including one dominant TCR accounting for 12.2% of all TCR reads. This TCR clone was also
219 present in paired peripheral blood SARS-CoV-2 specific CD8⁺ T cells (4% of reads), but not
220 in sorted CD4⁺ T cells (Figure 5f). As this sample was collected 2 months after viral clearance
221 and 80.4% of the nasal CD8⁺ T cells for this patient were of a TRM phenotype (Figure 5g),
222 this indicates that antigen-specific tissue-resident memory was induced. Of note, the number
223 of unique SARS-CoV-2 specific TCRs detected and their overlap between nose and peripheral
224 blood might be underestimated as blood CD8⁺ T cells were isolated based on reactivity
225 towards structural proteins, while CD8⁺ T cell reactivity is also directed against non-structural
226 proteins in severe COVID-19 patients³⁹⁻⁴¹. Taken together, we demonstrated SARS-CoV-2
227 specific CD8⁺ T cells can persist in the nasal mucosa months after viral clearance, based on
228 their activated phenotype and overlapping TCR clonotype with SARS-CoV-2 reactive CD8⁺ T
229 cells in blood. This is suggestive of the establishment of local protective immune memory
230 responses that could rapidly control and attenuate re-infections by SARS-CoV-2.

231

232 In conclusion, we provide the first comprehensive overview to date of how COVID-19 affects
233 the nasal mucosal immune system during acute infection and during early and later recovery
234 stages. Acute COVID-19 led to transient increases in granulocytes and monocyte subsets, a
235 NK cell subset and CD4⁺ T EM. Elements of this strong pro-inflammatory response positively
236 correlated with viral load and nasal neutrophil numbers in addition correlated negatively with
237 oxygen saturation in blood. We show several similarities with reports from blood, including a
238 strong CD4⁺ T EM cell response marked by markers of activation, but also exhaustion and
239 inhibition, as well as the presence of HLA-DR^{low} monocyte subsets in the nasal mucosa. A
240 striking difference from studies characterizing blood was the absence of a general
241 lymphopenia in the nasal mucosa. We also provided further characterization of cellular
242 subsets infiltrating the mucosa during disease, such as CD11c⁺ NK cells, CD123-expressing
243 differentiated macrophages and CD127 expression on CD16⁻ granulocytes. During early and
244 later recovery stages of disease most of the cell numbers progressively returned to levels
245 comparable to age-matched healthy donors. However, several phenotypic changes in nasal
246 immune populations persisted even during recovery. For example CD127-expressing
247 granulocytes remained elevated during convalescence, while also residual increased
248 activation of CD4⁺ and CD8⁺ T cells after hospital discharge was observed. Moreover, by
249 comparing nasal TCR clonotypes with antigen-specific cells from blood, we were able to
250 demonstrate that SARS-CoV-2 specific CD8⁺ T cells can seed the nasal tissue and these
251 tissue-resident memory cells can persist at least up to 2 months post viral clearance. Future
252 studies should focus on mucosal immune responses in SARS-CoV-2 infected people with only
253 mild symptoms to provide insights into which mucosal immune populations associate with
254 control of infection. Moreover, the collection of samples very early in infection before hospital
255 admission would allow to stratify and predict disease course. Likewise, this study highlights
256 the need for studying patients post infection to understand persistent immunological
257 perturbations following SARS-CoV-2 infection. Altogether, this study provides unique insights
258 into the mucosal immune cell dynamics both during acute and recovery of COVID-19.

259

260 **Acknowledgments**

261 We thank all patients and healthy volunteers for taking part in this study. This work was
262 supported by a MKMD-COVID-19 grant (no. 114025007) from ZonMW and Proefdiervrij. This
263 work was also supported by Wake Up To Corona crowdfunding by Leids Universitair Fonds.
264 SPJ is supported by a LUMC Gisela Thier Fellowship. Figure 1 was partly made with

265 BioRender (<https://biorender.com/>). The authors gratefully acknowledge the Flow cytometry
266 Core Facility (FCF) at LUMC, Leiden, Netherlands (<https://www.lumc.nl/research/facilities/fcf>),
267 coordinated by dr. K. Schepers and M. Hameetman, run by the FCF Operators E.F.E de Haas,
268 J.P. Jansen, D.M. Lowie, S. van de Pas, and G.IJ. Reyneveld (Directors: Prof. F.J.T. Staal
269 and Prof. J.J.M. van Dongen) for technical support in the mass cytometry studies.

270

271 The authors declare no competing interests.

272 **Methods**

273 **Study design and ethics**

274 In this prospective observational cohort study, adult patients with PCR-confirmed COVID-19
275 who were admitted to our academic hospital were recruited. All hospitalized patients had
276 hypoxia. The study was performed at the Leiden University Medical Center, Leiden, the
277 Netherlands, from patients included from April 2020 until December 2020. After informed
278 consent was obtained, longitudinal sampling was performed for the duration of the hospital
279 admission, and one convalescent sample was obtained at the outpatient follow-up
280 appointment, which was scheduled six weeks after hospital discharge. Ethical approval was
281 obtained from the Medical Ethical Committee Leiden-Den Haag-Delft (NL73740.058.20). The
282 trial was registered in the Dutch Trial Registry (NL8589). As ICU patients had substantial
283 breathing support, we were unable to collect nasal mucosal cells from patients on the ICU.
284 Twelve healthy donors were included in the study. These were all sixty years or older, and
285 with a male:female ratio of 2:1, in order to match the patient population. The healthy donors
286 had no recent history of symptoms of airway infection (fever, cough, hypoxia, rhinorrhea,
287 myalgia, anosmia and or ageusia or fatigue), and were included after confirmed negative
288 SARS-CoV-2 IgG.

289

290 **Nasal cell collection and storage**

291 Nasal cells were collected by gently scraping the nasal inferior turbinate using curettes (Rhino-
292 Pro®, Arlington Scientific), as described previously⁴², and placing them in a tube containing
293 pre-cooled 8mL sterile PBS containing 5mM EDTA (Life Technologies). Such samples provide
294 immune cells from the mucosa that are not found in the lumen (including lymphoid subsets)
295 ⁴², and have been used previously to study nasal immune responses during controlled viral
296 and bacterial infections ^{43,44}. Per patient and timepoint, two curettes from one nostril were
297 collected. Cells were dislodged by pipetting liquid up and down the tip of curette and spun
298 down at 300xg for 10' at 4°C. Supernatant was completely removed and cells were
299 resuspended in 500µL of PBS. For fixation, an equal amount of freshly prepared 8%
300 formaldehyde (Fisher Scientific) was then added, followed by 30 minutes incubation at room
301 temperature. Cells were then spun down at 800xg for 10'. The supernatant was completely
302 removed and the pellet resuspended in 1mL heat-inactivated fetal bovine serum containing
303 10% DMSO and moved to a cryovial. Cryovials were frozen in a Mr. Frosty Frosty™ freezing
304 container (ThermoFisher Scientific) at -80°C and moved to liquid nitrogen within three days.

305

306 **CyTOF staining**

307 Nasal samples were barcoded and measured in batches. In every batch, one aliquot of
308 PBMCs from a reference sample was included to be able to normalize staining between
309 batches. First, cells were thawed in 2mL RPMI + 50% FBS and spun down for 10' at 1600rpm
310 at room temperature. Supernatant was discarded by pipetting. Reference PBMC were washed
311 with 2mL of PBS and then fixed with 4% formaldehyde for 15' at room temperature. Reference
312 PBMC were washed 2x with 2mL BD Perm/Wash (BD). Nasal cells were washed 1x with 1mL
313 BD Perm/Wash, and if clumps were visible, cells were filtered over a 100µm filter
314 (ThermoFisher Scientific). Nasal cells and reference PBMCs were resuspended in 50µL
315 Perm/Wash and then 50µL barcode mix targeting β2 microglobulin (B2M) was added to each
316 individual sample in a 6-choose-3 scheme using Cadmiums 106, 110, 111, 112, 114 and 116
317 ^{45,46}. Samples were incubated for 30' at room temperature and then washed with 4mL Cell

318 Staining Buffer (Fluidigm). Cells were spun 5' at 800xg, supernatant removed and
319 resuspended and combined into 3mL of Perm/Wash. Cells were spun again 5' at 800xg and
320 were resuspended in 45µL Perm/Wash. FcR block (Biolegend, 5µL) and heparin (0.5µL,
321 100U/mL) were added to prevent aspecific binding of antibodies and cells were incubated for
322 20' at room temperature⁴⁷. Then 50µL of antibody cocktail (Table S1) was added, followed by
323 a 45' incubation at room temperature. Cells were then washed twice with 2mL Cell Staining
324 Buffer and spun down for 5' at 800xg. DNA was then stained overnight at 4°C using 1mL Fix
325 and perm buffer (Fluidigm) containing 1000x diluted Intercalator-Ir (Fluidigm). Cells were then
326 washed with Cell Staining Buffer, counted and divided into tubes of 1x10⁶ cells and pelleted
327 down. Tubes were then washed and resuspended in cell acquisition solution (CAS, Fluidigm)
328 with EQ Four Element Calibration Beads (Fluidigm) and acquired on a Helios mass cytometer
329 (Fluidigm) at the Flow cytometry Core Facility (FCF) of Leiden University Medical Center
330 (LUMC) in Leiden, Netherlands (<https://www.lumc.nl/research/facilities/fcf>).

331

332 **Data preprocessing and clustering**

333 An outline of data pre-processing steps is shown in Supplementary figure 6. Debris and
334 normalization beads were filtered from .FCS files using the 'CyTOFclean' package (v1.0.1)⁴⁸.
335 Single cells were then manually gated based on DNA stain and the 'CATALYST' package
336 (v1.12.2) and single-stain controls were used to compensate data using the non-negative
337 linear least squares method⁴⁹. One by one plots were used to confirm correct compensation
338 of data. Then epithelial and immune cells were manually gated based on CD45 and EpCAM
339 expression, with exclusion of cPARP positive apoptotic cells, as well as immune doublets
340 (CD14+CD3+, CD66b+CD3+, CD14+CD66b+). Subsequently, 'CATALYST' package
341 (v1.12.2) was used to debarcode immune and epithelial cells individually per batch. FCS files
342 were then normalized using the reference PBMCs and the CyTOFBatchAdjust package with
343 99 percentile scaling for each marker individually⁵⁰. The marker CD69 was not present in the
344 reference PBMC at sufficient levels to scale and was thus not normalized. Signal intensity and
345 clustering of reference samples before and after normalization was used to verify appropriate
346 normalization. Clustering of cells into populations was done using hierarchical stochastic
347 neighbor embedding (hSNE) or tSNE with Cytosplore software (v2.3.0,
348 <https://www.cytosplore.org/>), using all markers minus EpCAM and cPARP⁵¹. All t-SNE
349 analyses were performed with complexity = 30. Diffusion map of monocytes was created using
350 'destiny' package (v.3.2.0) with k = 1000, using the markers: HLA-DR, CD11c, CD163, ACE-
351 2, CD45RO, CD14, CD38, CD127, CD206, CD86, CD4, CD123 and CD45RA.

352

353 **SARS-CoV-2 reactive T-cell isolation**

354 PBMCs from convalescent COVID-19 patients were isolated from fresh whole blood using
355 Ficoll-Isopaque and cryopreserved until further use. PBMCs were thawed and immediately
356 used for overnight stimulation assay. For the stimulation assay, 1x10⁶ PBMCs were seeded
357 in 100µL IMDM (Lonza) + 10% FCS (Sigma) + 1,4% L-glutamine (Lonza) + 1% Pen/Strep
358 (Lonza) and in the presence of 1µg/mL SARS-CoV-2 peptide pool or 1% DMSO (negative
359 control). The SARS-CoV-2 peptide pool consisted of 15-mer peptides derived from
360 nucleocapsid (N) (Miltenyi, cat#130-126-699), membrane (M) (Miltenyi, cat#130-126-703) and
361 most immunogenic sequences from the spike protein (S) (Miltenyi, cat#130-126-701).
362 Peptides were dissolved and used according to manufacturer's protocol. After 16 hours the
363 PBMCs were washed and stained for CD4-FITC (BD, cat#555346), CD8-PeCy7 (BD,
364 cat#557746), CD154-Pacific Blue (Biolegend, cat#310820) and CD137-APC (BD,

365 cat#550890) for 30 minutes at 4°C. PBMCs were washed, stained and sorted in phenol red
366 free DMEM (Gibco) + 2% FCS + 1% Pen/Strep.

367

368 **TCR identification**

369 TCR β sequences were identified as previously described with minor modifications⁵². In brief,
370 RNA was isolated from 1x10² to 1x10⁶ cells using the ReliaPrep RNA cell Miniprep system
371 (Promega). cDNA was generated using an Oligo dT-I.S⁵³, SMARTScribe Reverse
372 Transcriptase (Takara, Clontech), and a SA.rt template switching oligo forward primer. If
373 needed the complete cDNA was pre-amplified for 18 cycles with I.S. primers that anneal both
374 to the SA.rt and oligo dT IS region. Barcoded TCR PCR product was generated in two rounds
375 of PCR. In the first PCR, TCR β product was generated, in a second PCR the first PCR product
376 was used to include a 2-sided barcode sequence that allows discrimination between TCRs of
377 different T cell populations. PCR products of different T cell populations were pooled after
378 which TCR sequences were identified by NovaSeq (GenomeScan). NovaSeq data were
379 analysed using MiXCR software to determine the V β family and CDR3 regions. CDR3 regions
380 were analysed in Rstudio and CDR3 sequences with ≤ 50 reads, that were non-functional or
381 occurred on all samples were excluded from the analysis.

382

383 **Statistical analysis**

384 Statistical differences in cellular abundance between groups were compared with a linear
385 mixed model, in which individual patients were included as random effect and groups (acute,
386 ERS, convalescent and healthy donors) as fixed effect, using the 'lme4' (v.1.1-23) and
387 'lmerTest' (v3.1-2) packages. Post-hoc comparison of the groups included in the model was
388 conducted with the 'emmeans' package (v1.4.8), using Tukey correction. For the comparison
389 of multiple subsets or lineages, Benjamini-Hochberg multiple-testing correction was used.
390 Correlation values were calculated with Spearman non-parametric tests. Marker expression
391 between groups was compared with Wilcoxon test, with Bonferroni correction for multiple
392 markers and groups as in Seurat⁵⁴. Statistical tests were performed two-tailed. All analyses
393 were performed with R version 4.0.1, except for the 'cytofclean' package done in R3.6.3, using
394 Rstudio (v1.2.5033)

395

396 **Data availability**

397 Raw data is available upon reasonable request from corresponding author under compliance
398 with ethical and regulatory approvals.

399 References

- 400 1 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
401 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513,
402 doi:10.1016/S0140-6736(20)30211-7 (2020).
- 403 2 Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe COVID-19.
404 *Nature* **584**, 463-469, doi:10.1038/s41586-020-2588-y (2020).
- 405 3 Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe
406 COVID-19 patients. *Science* **369**, 718+, doi:10.1126/science.abc6027 (2020).
- 407 4 Liu, J. Y. *et al.* Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019
408 coronavirus disease in the early stage. *J Transl Med* **18**, doi:ARTN 206 10.1186/s12967-020-
409 02374-0 (2020).
- 410 5 Maucourant, C. *et al.* Natural killer cell immunotypes related to COVID-19 disease severity.
411 *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd6832 (2020).
- 412 6 Mann, E. R. *et al.* Longitudinal immune profiling reveals key myeloid signatures associated
413 with COVID-19. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd6197 (2020).
- 414 7 Schulte-Schrepping, J. *et al.* Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell
415 Compartment. *Cell* **182**, 1419+, doi:10.1016/j.cell.2020.08.001 (2020).
- 416 8 Kuri-Cervantes, L. *et al.* Comprehensive mapping of immune perturbations associated with
417 severe COVID-19. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd7114 (2020).
- 418 9 Woodruff, M. C. *et al.* Extrafollicular B cell responses correlate with neutralizing antibodies
419 and morbidity in COVID-19. *Nat Immunol* **21**, 1506-1516, doi:10.1038/s41590-020-00814-z
420 (2020).
- 421 10 Zhang, J. J. *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,
422 China. *Allergy* **75**, 1730-1741, doi:10.1111/all.14238 (2020).
- 423 11 Rodriguez, L. *et al.* Systems-Level Immunomonitoring from Acute to Recovery Phase of
424 Severe COVID-19. *Cell Rep Med* **1**, 100078, doi:10.1016/j.xcrm.2020.100078 (2020).
- 425 12 Smith, N. *et al.* Distinct systemic and mucosal immune responses to SARS-CoV-2.
426 2021.2003.2001.21251633, doi:10.1101/2021.03.01.21251633 %J medRxiv (2021).
- 427 13 Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with COVID-
428 19. *Nat Med* **26**, 842-844, doi:10.1038/s41591-020-0901-9 (2020).
- 429 14 Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium-immune cell
430 interactions identified by single-cell analysis. *Nat Biotechnol* **38**, 970-979,
431 doi:10.1038/s41587-020-0602-4 (2020).
- 432 15 Szabo, P. A. *et al.* Analysis of respiratory and systemic immune responses in COVID-19
433 reveals mechanisms of disease pathogenesis. 2020.2010.2015.20208041,
434 doi:10.1101/2020.10.15.20208041 %J medRxiv (2020).
- 435 16 Trump, S. *et al.* Hypertension delays viral clearance and exacerbates airway
436 hyperinflammation in patients with COVID-19. *Nat Biotechnol*, doi:10.1038/s41587-020-
437 00796-1 (2020).
- 438 17 Winkley, K. *et al.* Immune cell residency in the nasal mucosa and COVID-19 severity across
439 the age range. 2021.2002.2005.21251067, doi:10.1101/2021.02.05.21251067 %J medRxiv
440 (2021).
- 441 18 Pandolfi, L. *et al.* Broncho-alveolar inflammation in COVID-19 patients: a correlation with
442 clinical outcome. *BMC Pulm Med* **20**, 301, doi:10.1186/s12890-020-01343-z (2020).
- 443 19 Wauters, E. *et al.* Discriminating mild from critical COVID-19 by innate and adaptive immune
444 single-cell profiling of bronchoalveolar lavages. *Cell Res* **31**, 272-290, doi:10.1038/s41422-
445 020-00455-9 (2021).
- 446 20 Zhao, Y. *et al.* Clonal expansion and activation of tissue-resident memory-like Th17 cells
447 expressing GM-CSF in the lungs of severe COVID-19 patients. *Sci Immunol* **6**,
448 doi:10.1126/sciimmunol.abf6692 (2021).

- 449 21 Grant, R. A. *et al.* Circuits between infected macrophages and T cells in SARS-CoV-2
450 pneumonia. *Nature* **590**, doi:10.1038/s41586-020-03148-w (2021).
- 451 22 Guillon, A., Hiemstra, P. S. & Si-Tahar, M. Pulmonary immune responses against SARS-CoV-2
452 infection: harmful or not? *Intensive Care Med* **46**, 1897-1900, doi:10.1007/s00134-020-
453 06170-8 (2020).
- 454 23 Diao, B. *et al.* Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus
455 Disease 2019 (COVID-19). *Frontiers in Immunology* **11**, doi:ARTN 827
456 10.3389/fimmu.2020.00827 (2020).
- 457 24 Pillay, J. *et al.* A subset of neutrophils in human systemic inflammation inhibits T cell
458 responses through Mac-1. *Journal of Clinical Investigation* **122**, 327-336,
459 doi:10.1172/Jci57990 (2012).
- 460 25 Reiné, J. *et al.* Dynamic changes in innate immune and T cell function and composition at the
461 nasal mucosa across the human lifespan. 576744, doi:10.1101/576744 %J bioRxiv (2019).
- 462 26 Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after
463 infection. *Science* **371**, doi:10.1126/science.abf4063 (2021).
- 464 27 Zhou, R. *et al.* Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.
465 *Immunity* **53**, 864-877 e865, doi:10.1016/j.immuni.2020.07.026 (2020).
- 466 28 Burt, B. M. *et al.* CD11c identifies a subset of murine liver natural killer cells that responds to
467 adenoviral hepatitis. *J Leukocyte Biol* **84**, 1039-1046, doi:10.1189/jlb.0408256 (2008).
- 468 29 Cervia, C. *et al.* Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild
469 versus severe COVID-19. *Journal of Allergy and Clinical Immunology* **147**, 545-+,
470 doi:10.1016/j.jaci.2020.10.040 (2021).
- 471 30 Taylor, P. R. *et al.* Macrophage receptors and immune recognition. *Annu Rev Immunol* **23**,
472 901-944, doi:10.1146/annurev.immunol.23.021704.115816 (2005).
- 473 31 Gabilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune
474 system. *Nature Reviews Immunology* **9**, 162-174, doi:10.1038/nri2506 (2009).
- 475 32 Kvedaraite, E. *et al.* Major alterations in the mononuclear phagocyte landscape associated
476 with COVID-19 severity. *P Natl Acad Sci USA* **118**, doi:ARTN e2018587118
477 10.1073/pnas.2018587118 (2021).
- 478 33 Nomura, Y. *et al.* Phenotype for activated tissue macrophages in histiocytic necrotizing
479 lymphadenitis. *Pathol Int* **59**, 631-635, doi:10.1111/j.1440-1827.2009.02418.x (2009).
- 480 34 Benard, A. *et al.* Interleukin-3 is a predictive marker for severity and outcome during SARS-
481 CoV-2 infections. *Nature Communications* **12**, doi:ARTN 1112 10.1038/s41467-021-21310-4
482 (2021).
- 483 35 Kelly, E. A. *et al.* Potential contribution of IL-7 to allergen-induced eosinophilic airway
484 inflammation in asthma. *J Immunol* **182**, 1404-1410, doi:10.4049/jimmunol.182.3.1404
485 (2009).
- 486 36 Pizzolla, A. *et al.* Resident memory CD8(+) T cells in the upper respiratory tract prevent
487 pulmonary influenza virus infection. *Sci Immunol* **2**, doi:10.1126/sciimmunol.aam6970
488 (2017).
- 489 37 Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: Tissue resident memory T
490 cells in mice and humans. *Sci Immunol* **4**, doi:10.1126/sciimmunol.aas9673 (2019).
- 491 38 Herndler-Brandstetter, D. *et al.* KLRG1(+) Effector CD8(+) T Cells Lose KLRG1, Differentiate
492 into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. *Immunity* **48**,
493 716-+, doi:10.1016/j.immuni.2018.03.015 (2018).
- 494 39 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
495 COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415,
496 doi:10.1016/j.cell.2020.05.015 (2020).

- 497 40 Ferretti, A. P. *et al.* Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize
498 Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. *Immunity* **53**,
499 1095-1107 e1093, doi:10.1016/j.immuni.2020.10.006 (2020).
- 500 41 Peng, Y. *et al.* Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in
501 UK convalescent individuals following COVID-19. *Nat Immunol* **21**, 1336-1345,
502 doi:10.1038/s41590-020-0782-6 (2020).
- 503 42 Jochems, S. P. *et al.* Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates
504 Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection
505 Compared to Nasal Wash. *PLoS One* **12**, e0169805, doi:10.1371/journal.pone.0169805
506 (2017).
- 507 43 Habibi, M. S. *et al.* Neutrophilic inflammation in the respiratory mucosa predisposes to RSV
508 infection. *Science* **370**, doi:10.1126/science.aba9301 (2020).
- 509 44 Jochems, S. P. *et al.* Inflammation induced by influenza virus impairs human innate immune
510 control of pneumococcus. *Nat Immunol* **19**, 1299-1308, doi:10.1038/s41590-018-0231-y
511 (2018).
- 512 45 Hartmann, F. J., Simonds, E. F. & Bendall, S. C. A Universal Live Cell Barcoding-Platform for
513 Multiplexed Human Single Cell Analysis. *Sci Rep* **8**, 10770, doi:10.1038/s41598-018-28791-2
514 (2018).
- 515 46 Zunder, E. R. *et al.* Palladium-based mass tag cell barcoding with a doublet-filtering scheme
516 and single-cell deconvolution algorithm. *Nat Protoc* **10**, 316-333,
517 doi:10.1038/nprot.2015.020 (2015).
- 518 47 Rahman, A. H., Tordesillas, L. & Berin, M. C. Heparin reduces nonspecific eosinophil staining
519 artifacts in mass cytometry experiments. *Cytometry A* **89**, 601-607,
520 doi:10.1002/cyto.a.22826 (2016).
- 521 48 Wainwright, J. cytofclean: Automatically Cleans Mass Cytometry (CyTOF) FCS files. (2020).
522 49 Helena L. Crowell, V. R. T. Z., Stéphane Chevrier and Mark D. Robinson. CATALYST:
523 Cytometry dATa anALYSIS Tools. (2020).
- 524 50 Schuyler, R. P. *et al.* Minimizing Batch Effects in Mass Cytometry Data. *Front Immunol* **10**,
525 2367, doi:10.3389/fimmu.2019.02367 (2019).
- 526 51 Holtt, T. *et al.* Cytosplore: Interactive Immune Cell Phenotyping for Large Single-Cell
527 Datasets. *Comput Graph Forum* **35**, 171-180 (2016).
- 528 52 van der Lee, D. I. *et al.* Mutated nucleophosmin 1 as immunotherapy target in acute myeloid
529 leukemia. *J Clin Invest* **129**, 774-785, doi:10.1172/JCI97482 (2019).
- 530 53 Picelli, S. *et al.* Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat*
531 *Methods* **10**, 1096-1098, doi:10.1038/nmeth.2639 (2013).
- 532 54 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902 e1821,
533 doi:10.1016/j.cell.2019.05.031 (2019).

534

535 Figure Legends

536 **Figure 1. CyTOF analysis of nasal immune cells during and post COVID-19 infection. a)**
537 *Patient timelines. For each included patient, symptom onset (purple cross), hospitalization*
538 *(black bar), and ICU stay (red bar) are indicated, aligned to the day of admission. The orange*
539 *x indicates one patient who was included but later transferred to a different hospital. One*
540 *patient was discharged and then re-admitted a day later. Blue diamonds indicate nasal*
541 *curettage samples. *one patient was hospitalized for unrelated reasons at time of positive test*
542 *and symptom onset, hospital admission was set at day of symptom onset. b) Hierarchical SNE*
543 *was used to cluster cellular landmarks on 37 markers, into 12 populations. Some of these*
544 *populations were then further divided into subpopulations in a second t-SNE embedding at a*
545 *data level, as indicated in the rectangles. c) Heatmap of marker expression per population.*
546 *Median intensity per population is shown after arcsin transformation. NK = natural killer cells.*
547 *ILC = innate lymphoid cells, mDC = myeloid dendritic cells, pDC = plasmacytoid dendritic cells,*
548 *Neutro = neutrophils, Trm = Tissue-resident memory, EM = effector memory, DP = double-*
549 *positive (CD4+CD8+), DN = double-negative (CD4-CD8-), EMRA = effector memory re-*
550 *expressing CD45RA. Treg = regulatory T cells.*

551 **Figure 2. Nasal cell lineage abundance during and post COVID-19. a)** Stacked bar charts
552 showing the composition of the nasal immune system in acute COVID-19 (red, n=9), during
553 the early recovery phase (post ICU but still in hospital, orange, n = 11), or in COVID-19
554 convalescence (5-6 weeks post hospital discharge, pink, n=16) or healthy donors (HD, blue,
555 n=12). For patients with multiple samples collected in hospital, only the first sample is shown.
556 **b)** Correlation between nasal immune and epithelial cells for hospitalized patients (left) and
557 convalescent patients and healthy donors (right) are shown. Ranks of individuals are shown
558 with color corresponding to group, as well as regression line and results from spearman
559 correlation analysis. **c)** Ratio of nasal immune cell types normalized to the number of epithelial
560 cells from the same sample. Individuals and boxplots are shown and paired samples between
561 are indicated by grey lines. If a cell type was not detected in at least one sample, half the value
562 of the lowest recorded number was added to each sample, prior to log transformation. pDC =
563 plasmacytoid dendritic cells, mDC = myeloid dendritic cells, NK = natural killer cells. *p<0.05,
564 ***p < 0.001 by linear-mixed model with group as fixed effect and individuals as random effect,
565 with post-hoc testing and Tukey multiple testing correction followed by Benjamini-Hochberg
566 correction for comparing multiple lineages.

567 **Figure 3. Nasal cell subsets abundance during and post COVID-19. a)** Heatmap showing
568 log₁₀ Relative abundance (RA) of cell clusters. **b)** Boxplots of cell clusters during acute COVID-
569 19 (red, 10 samples from 9 patients), during the early recovery phase (ERS, post ICU but still
570 in hospital, orange, 18 samples from 11 patients n = 11), or in COVID-19 convalescence (5-6
571 weeks post hospital discharge, pink, n=16) or healthy controls (blue, n=12). Samples are
572 plotted against day of hospital admission, with healthy donors plotted at the right axis
573 separated by a dashed line. *p<0.05, **p<0.01, ***p<0.001, by linear-mixed model with group
574 as fixed effect and individuals as random effect, with post-hoc testing and Tukey multiple
575 testing correction followed by Benjamini-Hochberg correction for comparing multiple subsets.
576 Only first sample per donor in a timepoint (acute or ERS) is shown, but all are included in
577 statistical model. **c)** Correlation plot between nasal immune populations and clinical
578 characteristics. Marginal pairwise correlations were calculated using Spearman's test between
579 characteristics, using temporally matched data from hospitalized patients. If viral load (VL)
580 data was not available for the time of nasal cell sampling, the closest timepoint with available
581 data was used. VL is calculated as 40-Ct of SARS-CoV-2 PCR, meaning higher values
582 indicate more virus. Rho values are depicted through size and color of symbol. Correlations
583 with a nominal p-value < 0.05 are denoted with an asterisk. Hierarchical clustering based on

584 Euclidian distance of the correlation matrix with complete linkage. Cells are indicated in red,
585 while clinical characteristics are indicated in black.

586 **Figure 4. Phenotypic changes of innate and adaptive cell subsets during and post**
587 **COVID-19 . a)** Percentages of monocytes expressing CD163, CD163 and CD206 or neither
588 (Classical). Subsets frequencies are shown for during acute COVID-19 (red, n=9 samples),
589 during the early recovery phase (post ICU but still in hospital, orange, n = 11), or in COVID-
590 19 convalescence (5-6 weeks post hospital discharge, pink, n=16) or healthy donors (blue,
591 n=12). Boxplots and individual datapoints are depicted with paired patient samples connected
592 by a grey line. Only the first sample per patient for a given timepoint/group is shown, although
593 all are used for statistical modeling. * $p < 0.05$, p-values by linear-mixed model with post-hoc
594 testing and Tukey multiple testing correction. HD = healthy donor, Conv = convalescent. **b)**
595 Diffusion map showing trajectory analysis of monocyte/macrophage subsets. All cells are
596 colored according to their clustered phenotype. **c)** Violin plots showing expression of HLA-DR
597 and CD123 on CD163+ CD206+ monocytes/macrophages. # $p < 0.001$ compared to healthy
598 donors and convalescent patients, using pairwise Wilcoxon test and Bonferroni correction for
599 multiple testing. **d)** Clustering of CD16- granulocytes using tSNE and Gaussian mean shift. **e)**
600 Proportion of cluster 1 within CD16- granulocytes. * $p < 0.05$, ** $p < 0.01$, p-values by linear-
601 mixed model with post-hoc testing and Tukey multiple testing correction. **f)** Violin plots showing
602 expression of CD127 per cluster.

603 **Figure 5. Activated SARS-CoV-2 specific T cells are present in the nasal mucosa after**
604 **recovery. a)** Phenotype of CD4+ T effector memory (EM) cells. Intensity for four
605 activation/exhaustion/regulatory markers are shown as violin plots, with box plots inlayed.
606 ** $p < 0.01$, *** $p < 0.001$, # $p < 0.001$ compared to all other groups, using pairwise Wilcoxon test
607 and Bonferroni correction for multiple testing. **b)** tSNE analysis of CD8+ TRM cells. Expression
608 of CD38, HLA-DR or Tbet overlaid onto tSNE embedding. Bottom-right, clustering of tSNE
609 using Gaussian mean shift, with clusters overlaid onto the embedding. Clusters numbers are
610 indicated. **c)** Two-dimensional kernel density estimation from tSNE embedding of cells
611 belonging to the 4 groups group. **d)** Heatmap showing median expression for all markers per
612 CD8+ T cell cluster. **e)** Percentage of CD8+ TRM belonging to either cluster 3 or cluster 5, or
613 all clusters expressing CD38. * $p < 0.05$, ** $p < 0.01$, p-values by linear-mixed model with post-
614 hoc testing and Tukey multiple testing correction. **f)** Bar plots showing the frequency of TCR
615 clonotypes in nasal samples collected from one severe donor, only clones with frequency >1%
616 are shown. Red colored bar indicates the clone that was also found in sorted SARS-CoV-2
617 specific CD8+ T cells. Venn diagram shows the overlap between TCR clones from nasal
618 sample and paired SARS-CoV-2 specific CD4+ T cells or CD8+ T cells in PBMC. **g)** Bar plot
619 showing nasal CD8+ T cell composition for patient with dominant SARS-CoV-2 specific clone.
620 Naive and EM cells were too infrequent to be visible and are not labeled for this sample.

621

Figures




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5